<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799287</url>
  </required_header>
  <id_info>
    <org_study_id>18C021</org_study_id>
    <nct_id>NCT05799287</nct_id>
  </id_info>
  <brief_title>A Study of Telitacicept in Patients With Primary IgA Nephropathy</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Telitacicept in Patients With IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Telitacicept in patients&#xD;
      with primary IgA nephropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of a 5-week screening period, a double-blind treatment period divided&#xD;
      into phase A and phase B. Eligible subjects will be randomly assigned in a 1:1 ratio to&#xD;
      receive either Telitacicept 240mg or placebo. Subjects will be given SC Telitacicept or&#xD;
      placebo once a week for a total of 39 doses in phase A and once every 2 weeks for a total of&#xD;
      32 doses in phase B.&#xD;
&#xD;
      Primary endpoint of phase A will be measured at week 39. Primary endpoint of phase B will be&#xD;
      measured at week 104.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2023</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in urine protein creatinine ratio (UPCR) (based on a 24-hour urine sample) at Week 39</measure>
    <time_frame>Week 39</time_frame>
    <description>Primary endpoint of phase A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized estimated glomerular filtration rate (eGFR) slope at Week 104</measure>
    <time_frame>Week 104</time_frame>
    <description>Primary endpoint of phase B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urine protein creatinine ratio (UPCR) (based on a 24-hour urine sample) at weeks 52, 78, and 104</measure>
    <time_frame>weeks 52, 78, and 104</time_frame>
    <description>Change from baseline in UPCR at weeks 52, 78, and 104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in estimated glomerular filtration rate (eGFR) at weeks 39, 52, 78 and 104</measure>
    <time_frame>weeks 39, 52, 78 and 104</time_frame>
    <description>Change from baseline in eGFR at weeks 39, 52, 78 and 104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urine albumin-to-creatinine ratio (UACR) (based on a 24-hour urine sample) at weeks 39, 52, 78 and 104</measure>
    <time_frame>weeks 39, 52, 78 and 104</time_frame>
    <description>Change from baseline in UACR (based on a 24-hour urine sample) at weeks 39, 52, 78 and 104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving urine protein creatinine ratio (UPCR) &lt; 0.8 g/g (based on a 24-hour urine sample) at weeks 39, 52, 78 and 104</measure>
    <time_frame>weeks 39, 52, 78 and 104</time_frame>
    <description>Proportion of subjects achieving UPCR &lt; 0.8 g/g (based on a 24-hour urine sample) at weeks 39, 52, 78 and 104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a 30% decrease in estimated glomerular filtration rate (eGFR) from baseline at Week 39</measure>
    <time_frame>Week 39</time_frame>
    <description>Proportion of patients with a 30% decrease in eGFR from baseline at Week 39</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized estimated glomerular filtration rate (eGFR) slope at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Annualized eGFR slope at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of 30% decrease in estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>up to 104 weeks</time_frame>
    <description>Time to first occurrence of 30% decrease in eGFR since the first dose of the study medicine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who received rescue therapy at weeks 52, 78, and 104</measure>
    <time_frame>weeks 52, 78, and 104</time_frame>
    <description>Proportion of subjects who received rescue therapy at weeks 52, 78, and 104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to composite endpoint event</measure>
    <time_frame>up to 104 weeks</time_frame>
    <description>The composite endpoint event is defined as initiation of maintenance renal dialysis (for at least 1 month), renal transplant, renal failure (eGFR &lt; 15 mL/min/1.73 m2 or greater than 30% decrease in eGFR from baseline), or death due to renal failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>up to 104 weeks</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in 24-hour urine protein at Week 39</measure>
    <time_frame>Week 39</time_frame>
    <description>Change from baseline in 24-hour urine protein at Week 39</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Telitacicept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be given Telitacicept 240 mg SC once a week in phase A for a total of 39 doses and once every 2 weeks in phase B for a total of 32 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be given placebo SC once a week in phase A for a total of 39 doses and once every 2 weeks in phase B for a total of 32 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Telitacicept</intervention_name>
    <description>Telitacicept 240 mg SC</description>
    <arm_group_label>Telitacicept</arm_group_label>
    <other_name>RC18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to Telitacicept</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary informed consent provided;&#xD;
&#xD;
          2. Male or female aged ≥ 18 years old;&#xD;
&#xD;
          3. IgA nephropathy confirmed by pathological biopsy;&#xD;
&#xD;
          4. During the screening period, UPCR ≥ 0.5 g/g based on 24-hour urine collection at visit&#xD;
             1 and/or visit 2 and at visit 3;&#xD;
&#xD;
          5. eGFR ≥ 30 mL/min per 1.73 m^2 (using the CKD-EPI);&#xD;
&#xD;
          6. Have been on a treatment regimen including ACEI/ARB for 12 weeks and on a stable use&#xD;
             of ACEI/ARB medication at the maximum tolerated dose/maximum allowable dose within 4&#xD;
             weeks prior to randomization. Subjects who use both ACEIs and ARBs will be excluded.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with clinically significant abnormal laboratory tests;&#xD;
&#xD;
          2. Patients with secondary IgA nephropathy;&#xD;
&#xD;
          3. Patients with other types of glomerular disease such as crescentic glomerulonephritis,&#xD;
             minimal change nephropathy with IgA deposition;&#xD;
&#xD;
          4. Renal transplant;&#xD;
&#xD;
          5. Patients with cirrhosis, as assessed by the investigator;&#xD;
&#xD;
          6. Patients who experienced any of the following cardiovascular and cerebrovascular&#xD;
             events within 24 weeks prior to randomization: myocardial infarction, unstable angina,&#xD;
             ventricular arrhythmia, NYHA Class II or higher heart failure, stroke, etc.;&#xD;
&#xD;
          7. Sitting office SBP&gt;140 mmHg or DBP&gt;90 mmHg during the screening period;&#xD;
&#xD;
          8. HbA1c&gt;8% (64mmol/mol);&#xD;
&#xD;
          9. Treatment with immunosuppressants (cyclophosphamide, azathioprine, mycophenolate,&#xD;
             leflunomide, tacrolimus, cyclosporine, Tripterygium wilfordii, etc.) within 12 weeks&#xD;
             prior to randomization;&#xD;
&#xD;
         10. Treatment with anti-CD20 therapy within 24 weeks prior to randomization;&#xD;
&#xD;
         11. Treatment with systemic glucocorticoid within 12 weeks prior to randomization;&#xD;
&#xD;
         12. Hospitalization or intravenous anti-infective therapy for active infection within 4&#xD;
             weeks prior to randomization;&#xD;
&#xD;
         13. Patients with active tuberculosis and untreated latent tuberculosis;&#xD;
&#xD;
         14. Hepatitis B: patients with active hepatitis (patients with positive HBsAg) or latent&#xD;
             hepatitis B (patients with positive HBcAb and positive HBV-DNA);&#xD;
&#xD;
         15. Patients with hepatitis C;&#xD;
&#xD;
         16. Patients with HIV;&#xD;
&#xD;
         17. Patients with malignancy within the past 5 years, except for treated cutaneous basal&#xD;
             cell carcinoma, cutaneous squamous cell carcinoma, colon polyps, or cervical cancer in&#xD;
             situ;&#xD;
&#xD;
         18. Pregnant women, lactating women, and subjects with childbearing plans during the&#xD;
             trial;&#xD;
&#xD;
         19. Unavoidable use of drugs with renal toxicity during the study;&#xD;
&#xD;
         20. Allergic to biological products of human origin;&#xD;
&#xD;
         21. Patients who have received any investigational therapy within 4 weeks or within 5&#xD;
             times the half-life of the investigational product (whichever is longer) prior to&#xD;
             randomization;&#xD;
&#xD;
         22. Live vaccination within 4 weeks prior to randomization;&#xD;
&#xD;
         23. Patients with COVID-19 infection within 4 weeks of randomization or patients with a&#xD;
             history of serious COVID-19 disease requiring hospitalization within 52 weeks prior to&#xD;
             screening;&#xD;
&#xD;
         24. Drug or alcohol abuse/dependence within 52 weeks prior to randomization;&#xD;
&#xD;
         25. Not suitable for the study in the opinion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yijishan Hospital of Wannan Medical College</name>
      <address>
        <city>Wuhu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital Affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Tsinghua Changgeng Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Shougang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Army Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Affiliated to Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Shenzhen Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenzhen Hospital of Southern Medical University</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhuhai People's Hospital</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guilin Medical College</name>
      <address>
        <city>Guilin</city>
        <state>Guangxi Zhuang Autonomous Region</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liuzhou Workers Hospital</name>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi Zhuang Autonomous Region</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guizhou Provincial People's Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Hebei University</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cangzhou Central Hospital</name>
      <address>
        <city>Cangzhou</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital of Qinhuangdao</name>
      <address>
        <city>Qinhuangdao</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xingtai People's Hospital</name>
      <address>
        <city>Xingtai</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia Autonomous Region</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Inner Mongolia Medical University</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia Autonomous Region</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changzhou No.2 People's Hospital</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Provincial People's Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuxi People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China-Japan Union Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jilin Province People's Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Northern Theatre Command of Chinese People's Liberation Army</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Central Hospital of Shenyang Medical College</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia Hui Autonomous Region</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Qianfoshan Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linyi People's Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanxi Bethune Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial People's Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sichuan Academy of Medical Sciences &amp; Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Yibin</name>
      <address>
        <city>Yibin</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Xinjiang Uygur Autonomous Region</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang Uygur Autonomous Region</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang Uygur Autonomous Region</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Yunnan Province</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinhua Municipal Central Hospital</name>
      <address>
        <city>Jinhua</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ningbo First Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ningbo Huamei Hospital, University of Chinese Academy of Sciences</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wenzhou People's Hospital</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 5, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Diseases</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Immune System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

